Fierce Biotech: Why Pheast’s CEO Has No Regrets About Transparent Approach Despite Competitors Circling

In an interview with Fierce Biotech, Pheast Therapeutics CEO Roy Maute discusses the growing interest in the biology and targets Pheast has helped pioneer, reinforcing the company’s differentiated position in oncology. Maute highlights Pheast’s science-driven approach to developing PHST001, including encouraging early clinical findings that supported expansion into Phase 1b combination studies. He also discusses the company’s broader pipeline and its strategy for translating novel tumor biology into differentiated therapeutics, including bispecific ADC PHST677. Read the full article here.